Michael Dundr, MD
General Practice · Columbus, OHNPI 1972711851
Payments from drug & device makers
Across 143 payments — averaging $14.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$454
- Pfizer$257
- AstraZeneca$200
- Exact Sciences$123
- GSK$85
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$80
- plus $945 from 28 others
What the payments were for
- Food & beverage$2,11399%
- Education$301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 31 | $454 |
| Pfizer | 25 | $257 |
| AstraZeneca | 7 | $200 |
| Exact Sciences | 5 | $123 |
| GSK | 6 | $85 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $80 |
| Novo Nordisk | 5 | $75 |
| Boehringer Ingelheim | 5 | $70 |
| Amgen(2 entities) | 5 | $68 |
| Novartis | 4 | $58 |
| Amarin Pharma, Inc. | 3 | $52 |
| Otsuka America Pharmaceutical, Inc. | 3 | $51 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $44 |
| Boston Scientific | 1 | $43 |
| Sanofi-aventis U.S. LLC | 3 | $40 |
| Lilly USA, LLC | 3 | $38 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $36 |
| Corcept Therapeutics | 2 | $35 |
| Merck | 3 | $35 |
| Aimmune Therapeutics, Inc. | 2 | $31 |
| Phathom Pharmaceuticals, Inc. | 2 | $28 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $27 |
| Teva Pharmaceuticals USA, Inc. | 2 | $27 |
| Avanir Pharmaceuticals, Inc. | 2 | $23 |
| Dexcom, Inc. | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Neurocrine Biosciences, Inc. | 1 | $17 |
| Urovant Sciences Inc | 1 | $17 |
| Bayer | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
| Gilead | 1 | $12 |
| Currax Pharmaceuticals LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,143 in reported general payments places this provider in the 90th percentile of 2,933 general practice providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 697 | $274,496 |
| TrulicityDulaglutide | 206 | $188,776 |
| JardianceEmpagliflozin | 315 | $171,835 |
| OzempicSemaglutide | 131 | $151,124 |
| FarxigaDapagliflozin Propanediol | 237 | $147,532 |
| Austedo XrDeutetrabenazine | 15 | $118,567 |
| XareltoRivaroxaban | 271 | $89,905 |
| JanuviaSitagliptin Phosphate | 144 | $84,174 |
| XifaxanRifaximin | 23 | $67,720 |
| EnbrelEtanercept | 15 | $66,578 |
| VraylarCariprazine Hcl | 58 | $64,124 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 82 | $57,131 |
| MounjaroTirzepatide | 39 | $44,075 |
| MyrbetriqMirabegron | 116 | $36,439 |
| LinzessLinaclotide | 49 | $35,564 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Nurtec Odt, Abrysvo | $257 | $327,046796 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $38 | $232,850245 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta | $70 | $197,453361 claims |
| AstraZenecaFarxiga, Symbicort, Lokelma | $200 | $181,880338 claims |
| Novo NordiskOzempic | $75 | $151,124131 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $27 | $118,56715 claims |
| AbbVieVraylar, Linzess, Creon | $454 | $111,325121 claims |
| MerckJanuvia | $35 | $84,174144 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $85 | $82,984135 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $80 | $67,72023 claims |
| AmgenEnbrel | $68 | $66,57815 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $17 | $21,32451 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,933 general practice providers in Ohio.
Other general practice in Columbus
- Luiz MeirellesColumbus$229K
- Daniel WardColumbus$68K
- Thomas McCartneyColumbus$27K
- David HallColumbus$20K
- Melissa BrownColumbus$6K
- Katie Vincer SearsColumbus$6K
- Corey RaymondSalem$288K
- Heather PetroffBroadview Heights$170K
- William HuntzingerSylvania$102K
- Megan WeisenbergerCincinnati$81K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.